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INTRODUCTION
Psoriatic arthritis (PsA) is an immune-mediated chronic inflammatory arthropathy-associated with psoriasis [1] . The occurrence of PsA has been estimated at between 6% and 42% of patients afflicted with psoriasis [2] [3] [4] [5] [6] , which occurs in 1-3% of the population [7] [8] [9] . The clinical manifestations of PsA include arthritis, enthesitis, dactylitis, spondylitis, psoriasis, and nail disease, with approximately 50% of patients also experiencing erosive joint damage within the first 2 years [10] . Thus, therapeutic principles should comprise management of disease in each tissue compartment, with the ultimate goal of impeding disease progression and maximizing function over time [11, 12] .
Until the advent of tumor necrosis factor (TNF)
inhibitors, treatment for PsA focused largely on the use of non-steroidal anti-inflammatory drugs (NSAIDs) and conventional disease-modifying anti-rheumatic drugs (DMARDs) despite a dearth of evidence showing their efficacy in clinical trials [13] . Nevertheless, clinical experience suggests that these agents are effective at reducing inflammation and treating some symptoms and signs and they remain the recommended first-line treatment option for patients with active PsA across several current international guidelines [11, 12] .
The development of anti-TNF therapies revolutionized the treatment of PsA, offering an effective biologic treatment for patients who showed a lack of efficacy and/or toxicity with NSAIDs and DMARDs [11, [14] [15] [16] . Extensive evidence accrued with several agents across numerous clinical trials and registries shows that anti-TNF agents are efficacious in the treatment of PsA. However, a number of unmet needs remain; for example, some patients have an inadequate response to, or intolerance of anti-TNF agents, long-term therapy with these agents is associated with decreasing drug survival rates, and the increased risk of infection may be of concern to some patients [16] [17] [18] .
Consequently, therapies with differing modes of action, including agents that were developed for the treatment of other rheumatic diseases (e.g., abatacept, rituximab, tocilizumab), have been tested for potential efficacy in PsA [16, 19] . Some of these agents, such as the phosphodiesterase 4 (PDE4) inhibitor apremilast [20] and the interleukin (IL)-12/23 inhibitor ustekinumab [21] , have demonstrated efficacy in clinical trials and are approved for use in PsA in the majority of developed countries. Nevertheless, because of inadequate efficacy, intolerance, or safety issues new treatments with alternative modes of action continue to be sought. Recently, genome-wide association studies, together with translational immunology analyses, have identified several novel molecular cascades involved in the pathogenesis of psoriasis and PsA, including particularly the IL-17 pathway [22] .
This article is based on previously conducted studies, and does not involve any new studies of human or animal subjects performed by any of the authors. Fig. 1) [29, [36] [37] [38] [39] .
THE IL-17 PATHWAY IN PSA
In patients with psoriasis, serum levels of total IL-17A (free and secukinumab-bound IL-17A) increase to plateau serum concentrations after administration of secukinumab. Following cessation of treatment, serum levels slowly decrease reflecting the kinetics of clearance of secukinumab-bound IL-17A. No significant changes in IL-17F are seen after secukinumab treatment, indicating that secukinumab selectively binds to and neutralizes free IL-17A [40] . In patients with plaque psoriasis, infiltrating epidermal neutrophils and various neutrophil-associated markers were significantly reduced in lesional skin of plaque psoriasis patients after 1-2 weeks of treatment with secukinumab, compared with baseline [40] .
The pharmacokinetic (PK) profile of secukinumab in patients with PsA is typical for an IgG1 mAb and similar to that seen in patients with psoriasis [40] . Based on population PK analysis in patients with plaque psoriasis, after initial weekly dosing during the first month, time to reach the maximum concentration of secukinumab was 31-34 days. to run for 2 years followed by a 3-year extension study and FUTURE 2 for the initial 52 weeks of study followed by an additional 4 years during which long-term efficacy and safety data will be collected.
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Observed values of ACR20 responses at Week 52 were 69.5% with secukinumab 150 mg and 66.9% with secukinumab 75 mg (Fig. 3) . Two-year follow-up data from FUTURE 1 confirmed the sustainability of these effects with long-term secukinumab treatment [42] .
In FUTURE 2, the primary endpoint was met with all secukinumab doses [43] . ACR20 response rates at Week 24 were 54.0% with secukinumab 300 mg (P\0.0001), 51.0% with 150 mg (P\0.0001), and 29.3% with 75 mg (P = 0.0399) versus 15.3% with placebo (Fig. 3) . Mean changes from baseline in DAS28-CRP and SF36-PCS were all significantly improved with secukinumab 300 and 150 mg versus placebo at Week 24 (Figs. 7, 8 ). Secukinumab 300 mg also significantly improved ACR50 and HAQ-DI (Figs. 4, 9 ). Other endpoints were not considered significant based on hierarchical testing. ACR50 responses were achieved by 35.0%, 35.0%, and 18.2% of patients in the secukinumab 300, 150, and 75 mg groups, respectively, compared with 7.1% in the placebo group (Fig. 4) . The clinical improvements induced by secukinumab in FUTURE 2 were sustained through to Week 52;
response rates were 64.0%, 64.0%, and 50.5%
with missing values imputed as nonresponse in the secukinumab 300, 150, and 75 mg groups, respectively. Observed ACR20 responses were 73%, 73%, and 67%, respectively (Fig. 3) (Fig. 11) ; 81.6% and 79.4% were free from enthesitis at Week 52 versus 37.6% and 36.1% at baseline.
Although numerical improvements in the proportion of patients achieving resolution of dactylitis and enthesitis with pooled secukinumab versus placebo were seen in FUTURE 2, these changes were not statistically significant when examined by a hierarchical testing methodology. Nevertheless, exploratory = 99  99  99  99  99  99  99  98  98  98  98  98  98  98  -N = 100  100  100  100  100  100 100  92  94  91  89  90  89  88  91  86  82  82  79  77  75  N =  ------95  95  95  94  92  91 [43, 48] .
Efficacy of Secukinumab in Patient Subgroups
Pre-specified subgroup analyses of FUTURE 1
and FUTURE 2 showed clinical benefits with secukinumab in patients who were anti-TNF treatment-naïve and patients who were prior inadequate responders to anti-TNF (TNFi-exposed). In both studies, significantly greater proportions of patients achieved ACR responses with secukinumab versus placebo after 24 weeks in both subgroups [42, 43] . In FUTURE 1, ACR20 response rates in the TNF-naïve subgroup using nonimputed data (missing values were imputed as non-response [non-responder imputation (NRI)] at Week-24 were 54.5% for secukinumab i.v.-150 mg and 55.6% for secukinumab i.v.-75 mg, compared with 17.5% in the placebo group. At Week 52 using observed data, the ACR20 response rates were 75.2% for secukinumab i.v.-150 mg and 73.2% for secukinumab i.v.-75 mg (Fig. 12a) . In the TNFi-exposed subgroup, the ACR20 responses at Week 24 were 39.0% and 38.3% (Fig. 12a) .
Similarly, in FUTURE 2, ACR20 response rates in the TNF-naïve subgroup using nonimputed data at Week 24 were 58.2% for secukinumab 300 mg, 63.5% for secukinumab 150 mg, 36.9% for secukinumab 75 mg, and 15.9% in the placebo group. At Week 52 using observed data, the ACR20 response rates were 79.4% for secukinumab 300 mg, 84.7% for secukinumab 150 mg, and 67.9% for (Fig. 12b) . In the TNFi-exposed subgroup, the ACR20 responses at Week 24 were 45.5%, 29.7% and 14.7% in the secukinumab 300, 150, and 75 mg groups, respectively, compared with 14.3% in the placebo group. The Week 52 observed data were 62.1% for secukinumab 300 mg, 37.8% for secukinumab 150 mg, and 63.2% for secukinumab 75 mg (Fig. 12b) .
Improvements with secukinumab versus placebo were also seen in both subgroups in a range of other endpoints, including PASI75/90, DAS-28, and HAQ-DI [42, 43, 49] . The magnitude of response was generally higher in the anti-TNF-naïve population [42, 43] . A dose effect emerged in this context, analogous to that observed in cutaneous psoriasis studies, since secukinumab 300 mg was associated with the greatest improvements in anti-TNF-IR patients. The efficacy of secukinumab was sustained for up to 52 weeks in both subgroups [49] . Finally, it is worth noting that in post hoc analyses, improvements in ACR response rates with secukinumab compared with placebo at Week 24 were similar regardless of concomitant MTX use [42, 43] .
Safety in Phase III Trials
Secukinumab was well-tolerated in patients with active PsA across FUTURE 1 and FUTURE 2 (Table 2 ) [42, 43] . More than 1200 patients were assessed for safety across the two FUTURE trials, with a mean exposure to secukinumab of 438.5 days in FUTURE 1 and 411.7 days in FUTURE 2 (Table 2) . Among these patients, the exposure-adjusted incidence rate of any adverse event in the secukinumab-treated patients for FUTURE 1 and FUTURE 2 was 471 and 307 per 100 patient-years, respectively (Table 2) . Across both studies, the most common adverse events were nasopharyngitis, upper respiratory tract infections, and headache (Table 2) .
Serious adverse events were also uncommon among secukinumab-treated patients. Discontinuation due to adverse events occurred in 23 (3.9%) secukinumab-treated patients in FUTURE 1 and 8 (2.1%) secukinumab-treated patients in FUTURE 2, compared with 5 (2.5%) and 4 (4.1%) patients in the placebo groups of FUTURE 1 and FUTURE 2, respectively.
Adverse events of special interest were similar between groups in both studies ( Secukinumab has a low potential for immunogenicity, as evidenced by the low incidence of treatment-emergent anti-drug antibodies (ADAs; i.e., tests that were positive during the study but negative at baseline). In 
